Home Stocks ESLA Estrella Immunopharma Inc. (NASDAQ: ESLA) Healthcare · Biotechnology
$0.33 +0.00 (+0.30%)
Last close · Nov 18, 2026 · NASDAQ USD
The Quantellect read. ESLA rose 0.30% in the Nov 18 session to $0.33. Short interest is 2.43% of float with a 14.72% borrow fee. One active firm covers the stock as of Nov 19, 2026; one active firm with a target averages $8.00 over 12 months. Descriptive summary of the data on this page, not a recommendation.
Momentum Neutral RSI (14) 41.0 (overbought above 70, oversold below 30)
Short interest 2.4% of float FINRA settlement Oct 30, 2026
SMA 10 — SMA 20 — SMA 50 — SMA 200 —
Price details unavailable for this range. ×
Chart loads when this section enters view.
Dated chart events require JavaScript on this compact chart. Open the full chart for dated events .
Text price and event history 6M plotted price range (ET) Range 6M First date — Last date — Open — High — Low — Close — Volume — Plotted bars 0
Plotted OHLCV bars No price bars are available for this range.
Event records Event records load after the price chart.
Split-adjusted daily prices · Price as of —
Initial 6M price range summary Range 6M First close — Last close — High — Low — Volume —
Open $0.34 Nov 18, 2026 session
Previous close $0.33 Nov 17, 2026 close
Day range $0.33 – $0.38 Nov 18, 2026 session
52-week range —
Volume 446.60K Nov 18, 2026 session
Average volume (30 calendar days) —
Market cap —
P/E (TTM) —
Forward P/E —
EPS (TTM) —
Dividend yield data unavailable —
Beta (5-year monthly vs SPY) —
Price history ESLA · NASDAQ · USD
Split-adjusted · volume in shares
Price history unavailable Retry
Notable price movement — · Notable price movement not available
Options flow — · Options flow not available
Q Score — · Q Score not available
Industry comparison — · Industry comparison not available
Upcoming events — · Upcoming events not available
Analyst consensus Insufficient coverage
0 Strong Buy
1 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 1 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $8.00
Average $8.00
High $8.00
As of Nov 19, 2026 across 1 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −0.40 −0.30 −0.20 −0.10 0.00 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 −$0.08 −$0.17 —
Q2 2026 −$0.09 −$0.05 —
Q1 2026 — −$0.05 —
Annual 2025 — −$0.35 —
Q3 2025 — −$0.13 —
Q2 2025 — −$0.15 —
Q1 2025 — −$0.06 —
Annual 2024 — −$0.27 —
Smart-money activity In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.
Date Type Who Action Amount Source
Oct 7, 2025 Insider buy Xu Jiandong Buy $1.3K Form 4 Sep 22, 2025 Insider buy Xu Jiandong Buy $1.2K Form 4 Sep 11, 2025 Insider buy Xu Jiandong Buy $104 Form 4 All smart-money activity →
News and press releases Year All 2026 Nov 16, 2026, 8:00 AM ET Oct 26, 2026, 8:00 AM ET All ESLA news → Company profile Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It
CEO Ms. Cynthia Pussinen
Headquarters EmeryVille, CA, United States
Employees 0
IPO date Sep 14, 2021
Sector Healthcare
Industry Biotechnology Q Score — · Q Score not available
Upcoming events — · Upcoming events not available
Analyst consensus Insufficient coverage
0 Strong Buy
1 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 1 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $8.00
Average $8.00
High $8.00
As of Nov 19, 2026 across 1 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −0.40 −0.30 −0.20 −0.10 0.00 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 −$0.08 −$0.17 —
Q2 2026 −$0.09 −$0.05 —
Q1 2026 — −$0.05 —
Annual 2025 — −$0.35 —
Q3 2025 — −$0.13 —
Q2 2025 — −$0.15 —
Q1 2025 — −$0.06 —
Annual 2024 — −$0.27 —
Company profile Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It
CEO Ms. Cynthia Pussinen
Headquarters EmeryVille, CA, United States
Employees 0
IPO date Sep 14, 2021
Sector Healthcare
Industry Biotechnology